Direkt zum Inhalt
Merck

A conserved mechanism for JNK-mediated loss of Notch function in advanced prostate cancer.

Science signaling (2023-11-07)
Cheng-Wei Wang, Marie Clémot, Takao Hashimoto, Johnny A Diaz, Lauren M Goins, Andrew S Goldstein, Raghavendra Nagaraj, Utpal Banerjee
ZUSAMMENFASSUNG

Dysregulated Notch signaling is a common feature of cancer; however, its effects on tumor initiation and progression are highly variable, with Notch having either oncogenic or tumor-suppressive functions in various cancers. To better understand the mechanisms that regulate Notch function in cancer, we studied Notch signaling in a Drosophila tumor model, prostate cancer-derived cell lines, and tissue samples from patients with advanced prostate cancer. We demonstrated that increased activity of the Src-JNK pathway in tumors inactivated Notch signaling because of JNK pathway-mediated inhibition of the expression of the gene encoding the Notch S2 cleavage protease, Kuzbanian, which is critical for Notch activity. Consequently, inactive Notch accumulated in cells, where it was unable to transcribe genes encoding its target proteins, many of which have tumor-suppressive activities. These findings suggest that Src-JNK activity in tumors predicts Notch activity status and that suppressing Src-JNK signaling could restore Notch function in tumors, offering opportunities for diagnosis and targeted therapies for a subset of patients with advanced prostate cancer.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Roche
cOmplete Mini Proteasehemmer-Cocktail, Tablets provided in a glass vial
Sigma-Aldrich
Anti-LDH-A Antibody, clone 5D2.1, clone 5D2.1, from mouse